drugset
drugset / Trial / NCT02286947

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

NCT02286947 ↗

Phase 2 Completed 24 enrolled Sarepta Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

Timeline

Start
2014-11
Primary completion
2017-04-21
Completion
2018-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Eteplirsen Antisense oligonucleotide 30 mg/kg Intravenous

Indications

Duchenne muscular dystrophy